Search

Your search keyword '"Vescio, Robert"' showing total 405 results
Start Over Author "Vescio, Robert"
405 results on '"Vescio, Robert"'

1. A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone

Author

Berenson, James R., Limon, Andrea, Rice, Stephanie, Safaie, Tahmineh, Boccia, Ralph, Yang, Honghao, Moezi, Mehdi, Lim, Stephen, Schwartz, Gary, Eshaghian, Shahrooz, Brobeck, Matthew, Swift, Regina, Eades, Benjamin M., Bujarski, Sean, Sebhat, Yohana, Ray, Rudra, Kim, Susanna, Del Dosso, Ashley, and Vescio, Robert

Published
2024
Full Text
View/download PDF

2. Low booster uptake in cancer patients despite health benefits

Author

Figueiredo, Jane C., Levy, Julia, Choi, So Yung, Xu, Alexander M., Merin, Noah M., Hamid, Omid, Lemos, Tucker, Nguyen, Nathalie, Nadri, Maimoona, Gonzalez, Alma, Mahov, Simeon, Darrah, Justin M., Gong, Jun, Paquette, Ronald L., Mita, Alain C., Vescio, Robert A., Salvy, Sarah J., Mehmi, Inderjit, Hendifar, Andrew E., Natale, Ronald, Tourtellotte, Warren G., Ramanujan, V. Krishnan, Huynh, Carissa A., Sobhani, Kimia, Reckamp, Karen L., and Merchant, Akil A.

Published
2024
Full Text
View/download PDF

3. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Author

Gordan, Lucio Navarro, Tan, Carlyn Rose, Vescio, Robert, Ye, Jing Christine, Schinke, Carolina, Medhekar, Rohan, Fu, Alex Z., Lafeuille, Marie-Hélène, Thompson-Leduc, Philippe, Khare, Vipin, Reitan, John, Milkovich, Gary, Kaila, Shuchita, Davies, Faith, and Usmani, Saad Z.

Published
2024
Full Text
View/download PDF

9. Does bortezomib influence pre‐transplant desensitization therapy or benefit post‐heart transplant outcomes for highly sensitized patients?

Author

Dhillon, Manvir, primary, Kobashigawa, Jon A., additional, Kittleson, Michelle, additional, Jain, Rashmi, additional, Patel, Nikhil, additional, Singer‐Englar, Tahli, additional, Zhang, Xiaohai, additional, Hakimi, Matthew, additional, Aintablian, Tamar, additional, Vescio, Robert, additional, Dilibero, Deanna, additional, Kransdorf, Evan, additional, Czer, Lawrence, additional, Nikolova, Andriana P., additional, and Patel, Jignesh K., additional

Published
2023
Full Text
View/download PDF

10. POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

Author

Gordan, Lucio, primary, Tan, Carlyn Rose, additional, Vescio, Robert, additional, Ye, Jing Christine, additional, Schinke, Carolina, additional, Medhekar, Rohan, additional, Fu, Alex Z., additional, Lafeuille, Marie-Hélène, additional, Thompson-Leduc, Philippe, additional, Khare, Vipin, additional, Reitan, John, additional, Milkovich, Gary, additional, Kaila, Shuchita, additional, Davies, Faith, additional, and Usmani, Saad Z., additional

Published
2023
Full Text
View/download PDF

11. Progression-Free Survival of Daratumumab vs. Bortezomib Triplet Combination with Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Author

Gordan, Lucio, primary, Tan, Carlyn Rose, additional, Vescio, Robert, additional, Ye, Jing Christine, additional, Schinke, Carolina, additional, Medhekar, Rohan, additional, Fu, Alex Z., additional, Lafeuille, Marie-Hélène, additional, Thompson-Leduc, Philippe, additional, Khare, Vipin, additional, Reitan, John, additional, Milkovich, Gary, additional, Kaila, Shuchita, additional, Davies, Faith, additional, and Usmani, Saad Z., additional

Published
2023
Full Text
View/download PDF

12. P-115 Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study

Author

Gordan, Lucio, primary, Tan, Carlyn Rose, additional, Vescio, Robert, additional, Ye, Jing Christine, additional, Schinke, Carolina, additional, Medhekar, Rohan, additional, Fu, Alex, additional, Lafeuille, Marie-Helene, additional, Thompson-Leduc, Philippe, additional, Khare, Vipin, additional, Reitan, John, additional, Milkovich, Gary, additional, Kaila, Shuchita, additional, Davies, Faith, additional, and Usmani, Saad, additional

Published
2023
Full Text
View/download PDF

13. MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study

Author

Gordan, Lucio, primary, Tan, Carlyn Rose, additional, Vescio, Robert, additional, Ye, Jing Christine, additional, Schinke, Carolina, additional, Medhekar, Rohan, additional, Fu, Alex Z., additional, Lafeuille, Marie-Hélène, additional, Thompson-Leduc, Philippe, additional, Khare, Vipin, additional, Reitan, John, additional, Milkovich, Gary, additional, Kaila, Shuchita, additional, Davies, Faith, additional, and Usmani, Saad Z., additional

Published
2023
Full Text
View/download PDF

15. Does bortezomib influence pre‐transplant desensitization therapy or benefit post‐heart transplant outcomes for highly sensitized patients?

Author

Dhillon, Manvir, Kobashigawa, Jon A., Kittleson, Michelle, Jain, Rashmi, Patel, Nikhil, Singer‐Englar, Tahli, Zhang, Xiaohai, Hakimi, Matthew, Aintablian, Tamar, Vescio, Robert, Dilibero, Deanna, Kransdorf, Evan, Czer, Lawrence, Nikolova, Andriana P., and Patel, Jignesh K.

Subjects
TREATMENT effectiveness, BORTEZOMIB, HEART transplantation, PROTEASOME inhibitors, OVERALL survival
Abstract

Background: The use of bortezomib which is a proteasome inhibitor has been demonstrated to be efficacious in small number of patients as a desensitization strategy in heart transplant. We reviewed our single center's experience using Bortezomib along with plasmapheresis as desensitization therapy for highly sensitized patients to assess pre‐ and post‐transplant outcomes. Method: We assessed 43 highly sensitized patients awaiting HTx (defined as cPRA > 50%) between 2010 and 2021 who underwent desensitization therapy with bortezomib. Only those patients who subsequently underwent HTx were included in this study. Enrolled patients received up to four doses of bortezomib (1.3 mg/m2) over 2 weeks in conjunction with plasmapheresis. The efficacy of PP/BTZ was assessed by comparing the calculated panel reactive antibodies to HLA class I or class II antigens. Post‐transplant outcomes including overall survival and incidence of rejection were compared to those of non‐sensitized patients (PRA < 10%, n = 649) from the same center. Results: The average cPRA prior to PP/BTZ was 94.5%. Post‐PP/BTZ there was no statistically significant decline in mean cPRA, class I cPRA, or class II cPRA, though the average percentage decrease in class I cPRA (8.7 ± 17.0%) was higher than the change in class II cPRA (4.4 ± 13.3%). Resulted were also replicated with C1q‐binding antibodies showing more effect on I class compared to class II (15.0 ± 37.4% vs. 6.8 ± 33.6%) as well as with 1:8 dilutional assay (14.0 ± 23.0% vs. 9.1 ± 34.9%). Additionally, PP/BTZ treated patients and the control group of non‐sensitized patients had similar overall 1 year survival (95.4 vs. 92.5%) but patients with PP/BTZ had increased incidence of AMR (79.1% vs. 97.1%, p = <.001), any treated rejection (62.8% vs. 86.7%, p = <.001) and de novo DSA development (81.4% vs. 92.5%, p =.007). Major side effects of PP/BTZ included thrombocytopenia (42%), infection requiring antibiotics (28%), and neuropathy (12%). Conclusion: The use of bortezomib in highly sensitized patients does not significantly lower circulating antibodies prior to heart transplantation. However, its use may improve the chances of obtaining an immuno‐compatible donor heart and contribute to acceptable post‐transplant outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Supplementary Data from Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

Author

Figueiredo, Jane C., primary, Merin, Noah M., primary, Hamid, Omid, primary, Choi, So Yung, primary, Lemos, Tucker, primary, Cozen, Wendy, primary, Nguyen, Nathalie, primary, Finster, Laurel J., primary, Foley, Joslyn, primary, Darrah, Justin, primary, Gong, Jun, primary, Paquette, Ronald, primary, Mita, Alain C., primary, Vescio, Robert, primary, Mehmi, Inderjit, primary, Basho, Reva, primary, Tourtellotte, Warren G., primary, Huynh, Carissa A., primary, Melmed, Gil Y., primary, Braun, Jonathan, primary, McGovern, Dermot P.B., primary, Mengesha, Emebet, primary, Botwin, Greg, primary, Prostko, John C., primary, Frias, Edwin C., primary, Stewart, James L., primary, Joung, Sandy, primary, Van Eyk, Jennifer, primary, Ebinger, Joseph E., primary, Cheng, Susan, primary, Sobhani, Kimia, primary, Reckamp, Karen L., primary, and Merchant, Akil, primary

Published
2023
Full Text
View/download PDF

17. Data from Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

Author

Figueiredo, Jane C., primary, Merin, Noah M., primary, Hamid, Omid, primary, Choi, So Yung, primary, Lemos, Tucker, primary, Cozen, Wendy, primary, Nguyen, Nathalie, primary, Finster, Laurel J., primary, Foley, Joslyn, primary, Darrah, Justin, primary, Gong, Jun, primary, Paquette, Ronald, primary, Mita, Alain C., primary, Vescio, Robert, primary, Mehmi, Inderjit, primary, Basho, Reva, primary, Tourtellotte, Warren G., primary, Huynh, Carissa A., primary, Melmed, Gil Y., primary, Braun, Jonathan, primary, McGovern, Dermot P.B., primary, Mengesha, Emebet, primary, Botwin, Greg, primary, Prostko, John C., primary, Frias, Edwin C., primary, Stewart, James L., primary, Joung, Sandy, primary, Van Eyk, Jennifer, primary, Ebinger, Joseph E., primary, Cheng, Susan, primary, Sobhani, Kimia, primary, Reckamp, Karen L., primary, and Merchant, Akil, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Data from A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma

Author

Berenson, James R., primary, To, Jennifer, primary, Spektor, Tanya M., primary, Martinez, Daisy, primary, Turner, Carley, primary, Sanchez, Armando, primary, Ghermezi, Matthew, primary, Eades, Benjamin M., primary, Swift, Regina A., primary, Schwartz, Gary, primary, Eshaghian, Shahrooz, primary, Stampleman, Laura, primary, Moss, Robert A., primary, Lim, Stephen, primary, and Vescio, Robert, primary

Published
2023
Full Text
View/download PDF

19. Successful autologous hematopoietic stem cell transplants using Salmonella positive products collected from asymptomatic donors

Author

Phou, Samantha, primary, Perez‐Alvarez, Ingrid, additional, Morgan, Margie, additional, Contreras, Deisy A., additional, Ben‐Aderet, Michael, additional, Gaddam, Emily, additional, Paquette, Ronald, additional, Vescio, Robert, additional, Pepkowitz, Samuel H., additional, Gibb, David R., additional, Zabner, Rachel, additional, and Klapper, Ellen B., additional

Published
2023
Full Text
View/download PDF

20. Stepping up: A Pilot Study Explores the Mobility Trajectory for Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Author

Low, Sarah, primary, Maldonado-Howell, Claudia, additional, Vescio, Robert, additional, Darrah, Justin, additional, Merin, Noah, additional, Flores, Jean, additional, Federizo, Yvette, additional, Uy, Leticia, additional, Guerrero, Margarita, additional, Lua, Michelle, additional, Daskivich, Timothy, additional, and Paquette, Ronald, additional

Published
2023
Full Text
View/download PDF

21. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Author

Lonial, Sagar, Weiss, Brendan M, Usmani, Saad Z, Singhal, Seema, Chari, Ajai, Bahlis, Nizar J, Belch, Andrew, Krishnan, Amrita, Vescio, Robert A, Mateos, Maria Victoria, Mazumder, Amitabha, Orlowski, Robert Z, Sutherland, Heather J, Bladé, Joan, Scott, Emma C, Oriol, Albert, Berdeja, Jesus, Gharibo, Mecide, Stevens, Don A, LeBlanc, Richard, Sebag, Michael, Callander, Natalie, Jakubowiak, Andrzej, White, Darrell, de la Rubia, Javier, Richardson, Paul G, Lisby, Steen, Feng, Huaibao, Uhlar, Clarissa M, Khan, Imran, Ahmadi, Tahamtan, and Voorhees, Peter M

Published
2016
Full Text
View/download PDF

23. Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma

Author

Berenson, James R., primary, Martinez, Daisy, additional, Safaie, Tahmineh, additional, Boccia, Ralph, additional, Yang, Honghao, additional, Moezi, Mehdi, additional, Lim, Stephen, additional, Schwartz, Gary, additional, Eshaghian, Shahrooz, additional, Swift, Regina, additional, Eades, Benjamin M., additional, Bujarski, Sean, additional, Regidor, Bernard, additional, Kim, Clara, additional, Kim, Susanna, additional, and Vescio, Robert, additional

Published
2022
Full Text
View/download PDF

24. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Author

Kumar, Shaji K, Berdeja, Jesus G, Niesvizky, Ruben, Lonial, Sagar, Laubach, Jacob P, Hamadani, Mehdi, Stewart, A Keith, Hari, Parameswaran, Roy, Vivek, Vescio, Robert, Kaufman, Jonathan L, Berg, Deborah, Liao, Eileen, Di Bacco, Alessandra, Estevam, Jose, Gupta, Neeraj, Hui, Ai-Min, Rajkumar, Vincent, and Richardson, Paul G

Published
2014
Full Text
View/download PDF

25. A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients

Author

Berenson, James R., primary, Kim, Clara, additional, Bujarski, Sean, additional, To, Jennifer, additional, Spektor, Tanya M., additional, Martinez, Daisy, additional, Turner, Carley, additional, Ghermezi, Matthew, additional, Eades, Benjamin M., additional, Swift, Regina A., additional, Schwartz, Gary, additional, Eshaghian, Shahrooz, additional, Moss, Robert A., additional, Lim, Stephen, additional, and Vescio, Robert, additional

Published
2022
Full Text
View/download PDF

30. Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.

Author

Berenson, James R., Martinez, Daisy, Safaie, Tahmineh, Boccia, Ralph, Yang, Honghao, Moezi, Mehdi, Lim, Stephen, Schwartz, Gary, Eshaghian, Shahrooz, Swift, Regina, Eades, Benjamin M., Bujarski, Sean, Regidor, Bernard, Kim, Clara, Kim, Susanna, and Vescio, Robert

Subjects
MULTIPLE myeloma, FLUORESCENCE in situ hybridization, RUXOLITINIB, METHYLPREDNISOLONE, MYELOPROLIFERATIVE neoplasms
Abstract

Summary: Although Janus kinase (JAK) inhibitors have demonstrated efficacy for treating autoimmune disorders and myeloproliferative neoplasms, their efficacy in treating other types of cancer has not been clearly demonstrated. We evaluated oral ruxolitinib (15 mg twice daily) with oral methylprednisolone (40 mg every other day) for multiple myeloma (MM) patients with progressive disease who had received a proteasome inhibitor, lenalidomide, glucocorticosteroids and three or more prior regimens. All of the planned 29 patients had been enrolled with follow‐up until 28 April 2022. Median lines of prior therapy were 6 (range 3–12). Cytogenetics and fluorescent in situ hybridization were evaluable in 28 patients; 9 (32%) and 17 (70%) patients showed high‐risk cytogenetics and/or 1q+, respectively. The overall response rate was 31%. The median duration of response was 13.1 (range 2.8–22.0) months. Median progression‐free survival rate was 3.4 (range 0.5–24.6) months, Overall, the treatment was well tolerated. The combination of ruxolitinib and methylprednisolone demonstrated significant clinical activity among previously heavily‐treated MM patients, and responses were achieved among patients who had high‐risk cytogenetics. This is the first clinical study to show activity of JAK inhibitors in combination with steroids for MM patients and expands the potential use of these drugs to those with cancers other than myeloproliferative neoplasms. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma

Author

Yashar, David, primary, Spektor, Tanya M., additional, Martinez, Daisy, additional, Ghermezi, Matthew, additional, Swift, Regina A., additional, Eades, Benjamin, additional, Schwartz, Gary, additional, Eshaghian, Shahrooz, additional, Lim, Stephen, additional, Vescio, Robert, additional, and Berenson, James R., additional

Published
2021
Full Text
View/download PDF

35. Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

Author

Figueiredo, Jane C., primary, Merin, Noah M., additional, Hamid, Omid, additional, Choi, So Yung, additional, Lemos, Tucker, additional, Cozen, Wendy, additional, Nguyen, Nathalie, additional, Finster, Laurel J., additional, Foley, Joslyn, additional, Darrah, Justin, additional, Gong, Jun, additional, Paquette, Ronald, additional, Mita, Alain C., additional, Vescio, Robert, additional, Mehmi, Inderjit, additional, Basho, Reva, additional, Tourtellotte, Warren G., additional, Huynh, Carissa A., additional, Melmed, Gil Y., additional, Braun, Jonathan, additional, McGovern, Dermot P.B., additional, Mengesha, Emebet, additional, Botwin, Greg, additional, Prostko, John C., additional, Frias, Edwin C., additional, Stewart, James L., additional, Joung, Sandy, additional, Van Eyk, Jennifer, additional, Ebinger, Joseph E., additional, Cheng, Susan, additional, Sobhani, Kimia, additional, Reckamp, Karen L., additional, and Merchant, Akil, additional

Published
2021
Full Text
View/download PDF

36. Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab

Author

Yashar, David, primary, Regidor, Bernard Sean S., additional, Jew, Scott Kristian, additional, Bujarski, Sean, additional, Goldwater, Marissa-Skye, additional, Swift, Regina, additional, Schwartz, Gary Edward, additional, Eshaghian, Shahrooz, additional, Vescio, Robert, additional, and Berenson, James R., additional

Published
2021
Full Text
View/download PDF

37. Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma

Author

Berenson, James R., primary, Martinez, Daisy, additional, Safaie, Tahmineh, additional, Silagan, Noemi, additional, To, Jennifer, additional, Spektor, Tanya M., additional, Forouzan, Eli, additional, Swift, Regina, additional, Eades, Benjamin, additional, Eshaghian, Shahrooz, additional, Schwartz, Gary, additional, Boccia, Ralph V., additional, Yang, Honghao H, additional, Moezi, Mehdi M., additional, Lim, Stephen, additional, and Vescio, Robert, additional

Published
2021
Full Text
View/download PDF

39. The Box Cars

Author

Vescio, Robert

Subjects
The Box Cars (Picture story) -- Vescio, Robert -- King, Cara -- Book reviews, Family and marriage, Library and information science, Publishing industry
Abstract

The Box Cars Robert Vescio, author Cara King, illustrator EK Books c/o Exisle Publishing www.exislepublishing.com.au 9781925335835, $17.99, HC, 32pp, www.amazon.com Liam and Kai are the best of friends. They do [...]

Published
2019

47. Longitudinal Vaccine-Induced Humoral Immune Response in Cancer Patients

Author

Figueiredo, Jane C., primary, Merin, Noah M., additional, Hamid, Omid, additional, Choi, So Yung, additional, Lemos, Tucker, additional, Cozen, Wendy, additional, Nguyen, Nathalie, additional, Finster, Laurel, additional, Foley, Joslyn, additional, Darrah, Justin, additional, Gong, Jun, additional, Paquette, Ronald, additional, Mita, Alain C., additional, Vescio, Robert, additional, Mehmi, Inderjit, additional, Basho, Reva, additional, Tourtellotte, Warren G., additional, Huynh, Carissa A., additional, Melmed, Gil Y., additional, Braun, Jonathan, additional, McGovern, Dermot, additional, Mengesha, Emebet, additional, Botwin, Greg, additional, Prostko, John C., additional, Frias, Edwin C., additional, Stewart, James L., additional, Joung, Sandy, additional, Van Eyk, Jennifer, additional, Ebinger, Joseph E., additional, Cheng, Susan, additional, Sobhani, Kimia, additional, Reckamp, Karen L., additional, and Merchant, Akil, additional

Published
2021
Full Text
View/download PDF

49. Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Author

Berenson, James R., primary, Silagan, Noemi, additional, To, Jennifer, additional, Spektor, Tanya M., additional, Martinez, Daisy, additional, Sanchez, Armando J., additional, Forouzan, Eli, additional, Swift, Regina, additional, Eades, Benjamin, additional, Schwartz, Gary, additional, Eshaghian, Shahrooz, additional, Boccia, Ralph V., additional, Yang, Honghao Hank, additional, Lim, Stephen, additional, and Vescio, Robert, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results